A Day in the Life of an Ophthalmic Surgeon™: Who’s in Your Waiting Room? Challenging Cases in Refractive Cataract Surgery (CME Monograph)

Activity Description

Cataract surgery has been recognized as one of the safest and most effective surgical procedures for many years, and innovations for preoperative, intraoperative, and postoperative care are enabling improved outcomes in all settings. In this case-based program, experts provide insights on planning and performing refractive cataract surgery to achieve success and patient satisfaction in challenging situations. The desired results of this activity are the optimization of outcomes of cataract surgery.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Review appropriate preoperative assessments in all patients undergoing cataract surgery
  • Use evidence-based medication regimens for inflammation and infection control in patients undergoing cataract surgery
  • Select the optimal intraocular lens for individual patients
  • Review advances in femtosecond cataract surgery technology
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
08/01/2020
Course expires: 
08/31/2021
Cost:
$0.00

Faculty

Eric D. Donnenfeld, MD (Chair)
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Founding Partner
Ophthalmic Consultants of Long Island and Connecticut
Garden City, New York

Neel R. Desai, MD
Director, Cornea, Cataract, and Refractive Surgery
The Eye Institute of West Florida
Tampa, Florida

Preeya K. Gupta, MD
Associate Professor of Ophthalmology
Cornea & Refractive Surgery
Duke University Eye Center
Durham, North Carolina

Mitchell A. Jackson, MD
Founder and CEO
Jacksoneye
Lake Villa, Illinois

Disclosure Policy Statement

It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

Disclosures

Neel R. Desai, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Royalty: Bausch & Lomb Incorporated; and LeMaitre; Consulting/Advisory Board: Abbott Medical Optics; Alcon; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; LENSAR, LLC; Lenstec, Inc; Lumenis; Moria; Nicox; Novartis Pharmaceuticals Corporation; Rapid Pathogen Screening, Inc; ScienceBased Health; TearScience; and Valeant; Contracted Research: Alcon; Avedro, Inc; Bausch & Lomb Incorporated; Bio-Tissue; Lenstec, Inc; and Lumenis; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Abbott Medical Optics; Alcon; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; LENSAR, LLC; Lenstec, Inc; Lumenis; Moria; Nicox; Novartis Pharmaceuticals Corporation; Rapid Pathogen Screening, Inc; ScienceBased Health; TearScience; and Valeant; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Abbott Medical Optics; Allergan; Bio-Tissue; Johnson & Johnson Vision Care, Inc; and Novartis Pharmaceuticals Corporation.

Eric D. Donnenfeld, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: AcuFocus, Inc; Alcon; Allegro Ophthalmics, LLC; Allergan; Avedro, Inc; Bausch & Lomb Incorporated; Beaver-Visitec International; BlephEx; CorneaGen; Dompé farmaceutici SpA; ELENZA, Inc; EyePoint Pharmaceuticals; ForSight Labs, LLC; Glaukos Corporation; Icon Bioscience, Inc; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; Katena Products, Inc; LacriSciences LLP; LensGen; Mati Therapeutics, Inc; Merck & Co., Inc; Mimetogen Pharmaceuticals; NanoWafer, Inc; NovaBay Pharmaceuticals, Inc; Novaliq GmbH Germany; Novartis Pharmaceuticals Corporation; OcuHub LLC; Oculis; Odyssey Medical, Inc; Omega Ophthalmics; Omeros Corporation; Orasis Pharmaceuticals; Oyster Point Pharma, Inc; Pfizer Inc; PogoTec; PRN; Rapid Pathogen Screening, Inc; Retear, Inc; Shire; Strathspey Crown; Sun Pharmaceutical Industries, Inc; Surface; TearLab Corporation; TrueVision; Veracity Innovations LLC; and Zeiss; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): AcuFocus, Inc; Alcon; Allegro Ophthalmics, LLC; Allergan; Avedro, Inc; Bausch & Lomb Incorporated; Beaver-Visitec International; BlephEx; CorneaGen; Dompé farmaceutici SpA; ELENZA, Inc; EyePoint Pharmaceuticals; ForSight Labs, LLC; Glaukos Corporation; Icon Bioscience, Inc; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; Katena Products, Inc; LacriSciences LLP; LensGen; Mati Pharmaceuticals, Inc; Merck & Co., Inc; Mimetogen Pharmaceuticals; NanoWafer, Inc; NovaBay Pharmaceuticals, Inc; Novaliq GmbH Germany; Novartis Pharmaceuticals Corporation; OcuHub LLC; Oculis; Odyssey Medical, Inc; Omega Ophthalmics; Omeros Corporation; Orasis Pharmaceuticals; Oyster Point Pharma, Inc; Pfizer Inc; PogoTec; PRN; Rapid Pathogen Screening, Inc; Retear, Inc; Shire; Strathspey Crown; Sun Pharmaceutical Industries, Inc; Surface; TearLab Corporation; TrueVision; Veracity Innovations LLC; and Zeiss.

Preeya K. Gupta, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Aurea Medical; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; New World Medical, Inc; Novartis Pharmaceuticals Corporation; NovaBay Pharmaceuticals, Inc; Ocular Science; ReGenTree, LLC; Shire; Sight Sciences; Sun Pharmaceutical Industries, Inc; TearLab Corporation; and Zeiss.

Mitchell A. Jackson, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Bausch & Lomb Incorporated; EyePoint Pharmaceuticals; Johnson & Johnson Vision Care, Inc; LENSAR, LLC; Novartis Pharmaceuticals Corporation; Ocular Therapeutix, Inc; Omeros Corporation; and Sun Pharmaceutical Industries, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alcon.

Denise Visco, MD, MBA, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Cassini Technologies; LENSAR, Inc; Omeros Corporation; and Zeiss; Contracted Research: Cassini Technologies; LENSAR, Inc; and Omeros Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Cassini Technologies; LENSAR, Inc; Omeros Corporation; and Zeiss.

New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure

Priti Batta, MD, has no relevant commercial relationships to disclose.

Editorial Support Disclosures

Cheryl Guttman-Krader; Melissa Carter, MS; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.

Disclosure Attestation

The contributing physicians listed above have attested to the following:

  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Accreditation Statement

imageThe New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.

AMA Credit Designation Statement

The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement

This continuing medical education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies

https://www.nyee.edu/education/cme

CME Provider Contact Information

For questions about this activity, call 917-270-7571.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Bausch & Lomb Incorporated, EyeNet, or the American Academy of Ophthalmology.

This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 194

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME information for this activity.

Learning Method and Medium

This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.